Paul D. Burgess bought CERE once, on Aug 4, 2023

Paul D. Burgess is a biotechnology executive and corporate insider with more than 20 years of experience in biotech and pharmaceutical organizations.( He has served as Chief Business Development and Strategic Operations Officer at Cerevel Therapeutics Holdings, Inc. (CERE), where he led business development, strategy, and quality functions and reported insider transactions as “See Remarks” in SEC filings.( Burgess has also been identified as an insider holder of Cerevel shares and has filed multiple Form 4 reports related to his equity transactions in the company.(

Prior to joining Cerevel, Burgess was Chief Operating Officer and Chief Legal Officer at Translate Bio, where he oversaw business development, legal, program management, quality, technical operations, and partner collaborations and helped guide the company through its sale to Sanofi in 2021.( Earlier in his career, he held legal and corporate roles at several life sciences companies, including Scholar Rock, Civitas Therapeutics, BIND Therapeutics, and Transform Pharmaceuticals, and worked in the laboratory at Genetics Institute.( Burgess holds a J.D. degree (as indicated by Scholar Rock’s appointment announcement) and is recognized for his expertise in intellectual property, corporate development, and strategic operations across the biotech sector.(

Written by Perplexity from public sources.